New CAR T-Cell therapy shows promise for tough blood cancers

NCT ID NCT06253663

First seen Nov 01, 2025 · Last updated Apr 25, 2026 · Updated 19 times

Summary

This study tests a treatment called KTE-X19, a type of cell therapy that uses a patient's own immune cells to fight cancer. It is for Japanese adults with two types of blood cancer that have come back or not responded to other treatments: mantle cell lymphoma and B-cell acute lymphoblastic leukemia. The study will check how safe and effective this therapy is, focusing on tumor shrinkage and remission rates.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Chiba University Hospital

    Chiba, 260-8677, Japan

  • Hokkaido University Hospital

    Hokkaido, 060-8648,, Japan

  • Juntendo University Hospital

    Tokyo, 113-8431, Japan

  • Kyoto University Hospital

    Kyoto, 606-8507, Japan

  • Kyushu University Hospital

    Fukuoka, 812-8582, Japan

  • National Cancer Center Hospital

    Tokyo, 104-0045, Japan

  • Okayama University Hospital

    Okayama, 700-8558, Japan

  • Tohoku University Hospital

    Miyagi, 980-8574, Japan

  • Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital

    Tokyo, 113-8677, Japan

Conditions

Explore the condition pages connected to this study.